Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EBITDA (2021 - 2025)

Historic EBITDA for Dare Bioscience (DARE) over the last 5 years, with Q3 2025 value amounting to -$3.6 million.

  • Dare Bioscience's EBITDA rose 2401.21% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.5 million, marking a year-over-year decrease of 39317.45%. This contributed to the annual value of -$4.1 million for FY2024, which is 8633.95% up from last year.
  • Latest data reveals that Dare Bioscience reported EBITDA of -$3.6 million as of Q3 2025, which was up 2401.21% from -$4.0 million recorded in Q2 2025.
  • Dare Bioscience's EBITDA's 5-year high stood at $12.9 million during Q2 2024, with a 5-year trough of -$15.8 million in Q4 2022.
  • Over the past 5 years, Dare Bioscience's median EBITDA value was -$6.8 million (recorded in 2024), while the average stood at -$5.9 million.
  • Per our database at Business Quant, Dare Bioscience's EBITDA tumbled by 326162.03% in 2023 and then skyrocketed by 24698.8% in 2024.
  • Over the past 5 years, Dare Bioscience's EBITDA (Quarter) stood at -$9.5 million in 2021, then crashed by 65.47% to -$15.8 million in 2022, then skyrocketed by 68.29% to -$5.0 million in 2023, then dropped by 11.47% to -$5.6 million in 2024, then soared by 36.19% to -$3.6 million in 2025.
  • Its EBITDA stands at -$3.6 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$4.4 million for Q1 2025.